ARTICLE | Finance

Global access

How Vivo could help Chinese cancer, autoimmune play InnoCare go global

February 16, 2018 9:18 PM UTC

Vivo Capital could help InnoCare Pharma Ltd. seek global development partners as the Chinese cancer and autoimmune company evaluates its first four candidates in the clinic.

Vivo, a new investor, led an untranched $55 million venture round for InnoCare on Feb. 9. Seed investor Jianxin Capital also participated...

BCIQ Company Profiles

InnoCare Pharma Ltd.